[Active immunotherapy in acute lymphoid leukemia in children. Influence of several factors on the results].
D000293:Adolescent; D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D001856:Bone Marrow Examination; D064987:Cell- and Tissue-Based Therapy; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007223:Infant; D007231:Infant, Newborn; D007945:Leukemia, Lymphoid / Q000145:classification / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012075:Remission, Spontaneous; D012189:Retrospective Studies; D014750:Vincristine / Q000627:therapeutic use
D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D014750:Vincristine; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin
L'immunothérapie active dans les leucémies aigues lymphoides de l'enfant. Influence de divers facteurs sur les résultats.